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Introduction
Atopic dermatitis (atopic eczema, dermatitis eczema, 
eczematous dermatitis, neurodermititis), (latin: der-
matitis atopica), also known as endogenous eczema is 
a chronic, relapsing inflammatory skin disease, which 
is characterized by skin lesions. The pathogenesis of 
AD is complex and still not fully understood. It is con-
sidered that all the interactions that occur between the 
genetically determined impairment of the structure 
and function of the epidermal barrier, the dysregulated 
immune and inflammatory response, environmental 
factors and infectious agents are engaged in the patho-
physiology of AD (Ring et al., 2012). Lichenification 
of the skin and pruritis, a very burdensome symptom, 
are distinctive manifestations of AD. The Hanifin and 
Rajka diagnostic criteria for AD are used to diagnose 
this skin disease (Hanifin and Rajka, 1980). 
Research conducted in recent years has brought 
two hypotheses to light that attempt to explain the 
pathogenesis of atopic dermatitis. The first hypothesis 
assumes that the initiating cause of the development 
of AD are immunological disorders. The initial stage of 
AD is characterized by a dominance of Th2 cells that 
secrete proinflammatory cytokines IL-4, IL-5, IL-13 and 
IgE. However, AD begins to shift into the chronic phase, 
Th1 cells begin to dominate. These immune aberrations 
cause inflammatory changes in the epidermis trigger-
ing epidermal barrier dysfunction. This hypothesis 
is called the “inside-to-outside hypothesis”. Another 
concept presumes that there is a fundamental dysfunc-
tion of epithelial cells and so an impaired epidermal 
barrier. The presence of this defect may lead to the 
penetration of the epidermal barrier by allergens or 
other irritants inducing a secondary immune response 
in the skin. This hypothesis is named the “outside-to-
inside hypothesis”. Since the discovery of the muta-
tion in the filaggrin (FLG) gene in a significant num-
ber of patients, researchers have begun to favour the 
second hypothesis as an explanation for the onset of 
AD (Palmer et al., 2006; Cork et al., 2009; Werfel, 2009; 
Bussmann et al., 2011).
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A b s t r a c t
Staphylococcus aureus colonizes the mucous membrane of the nasal vestibule of a significant number of healthy people. These microorgan-
isms are opportunistic pathogens, that in favorable conditions, may cause infections of various course, location or manifestation. Second-
ary infections emerge in cases when other risk factors contribute to such a change. One of the diseases during which S. aureus changes its 
saprophytic character to a pathogenic one is atopic dermatitis (AD), an allergic skin condition of a chronic and recurrent nature. Patients 
with AD are highly predisposed to secondary staphylococcal infections due to active S. aureus colonization of the stratum corneum, dam-
age of the skin barrier or a defective immune response. Microorganisms present in skin lesions destroy the tissue by secreting enzymes 
and toxins, and additionally stimulate secondary allergic reactions. The toxins secreted by strains of S. aureus also act as superantigens and 
penetrate the skin barrier contributing to a chronic inflammation of the atopic skin lesions. The S. aureus species also releases proinflam-
matory proteins, including enzymes that cause tissue damage. When initiating treatment it is particularly important to properly assess that 
the onset of the secondary bacterial infection is caused by S. aureus and thus justifying the inclusion of antibiotic therapy. Depending on 
the severity and extent of the staphylococcal infection, topical antibiotics are used, usually mupirocin or fusidic acid, or general antibiotic 
treatment is introduced. Another therapeutic strategy without antibiotics has given a positive effect in patients.
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It is also known that dendritic cells (specifically 
Langerhans cells), keratinocytes, mast cells and eosin-
ophils are key elements in the pathogenesis of AD. 
Dysfunction of these regulatory cells initiates a patho-
logical process that leads to the development of symp-
tomsin the course of atopic dermatitis (Werfel, 2009; 
Boguniewicz and Leung, 2011).
Epidemiology
Statistically, atopic dermatitis is one of the most 
common allergic conditions after hay fever and asthma. 
It affects nearly 30% of children and approximately 5% 
of adults who often develop secondary bacterial infec-
tions of the skin lesions (Nakamura et al., 2013). AD is 
an allergic condition that is showing a steady annual 
growth rate of 4% on a global scale. About 3% of adults 
suffer from AD in Poland. Residents of larger cities are 
more prone to develop AD than residents of rural areas 
(Sybilski et al., 2015). AD is often accompanied by other 
allergic conditions such as atopic asthma or allergic 
rhinitis (Lis et al., 2002).
The course of AD can be divided into the follow-
ing phases: infantile, childhood, adolescent and adult. 
These phases are distinguished by the location of skin 
lesions and course of the disease (Nutten, 2015). Obser-
vations show a higher prevalence of AD development 
in women than in men (Sybilski et al., 2015).
Colonization of healthy skin
by microorganisms
Changes in the microflora of patients with AD. The 
composition of a person’s normal microflora depends 
on the colonized area of the human host. Generally 
however, the human microbial population consists of 
coagulase negative staphylococci, mainly Staphylococ-
cus epidermidis, Staphylococcus haemolyticus, Staphylo-
coccus hominis; Propionibacterium acnes, and yeasts of 
the genus Malassezia, most commonly the Malassezia 
restricta and Malassezia globosa species. All of these 
microorganisms are present on the skin surface and in 
skin folds as well as in hair follicles. Smaller populations 
of other species may also be identified: Micrococcus sp., 
Aerobacter sp. and Proteus sp. and in less abundance 
others (Wiburg et al., 1984; Grice and Serge, 2011).
The opportunistic pathogen Staphylococcus aureus 
may be a component of the normal microbial flora of 
the skin and according to various authors, it may be 
found in 5% to 100% of healthy individuals. However, 
a vast majority of people are either permanent or tran-
sient carriers of this species in the nasal vestibule (Kloos 
and Schleifer, 1986).
A characteristic feature of patients with AD is the 
abundant presence of bacteria of the genus Staphylo-
coccus in comparison to healthy individuals (Table I). 
Results show an increased number of coagulase nega-
tive staphylococci that belong to the normal microflora 
as well as of S. aureus that triggers immune responses. 
Strains of the bacterial species S. aureus are present on 
the skin of patients and/or in the mucous membrane of 
the nasal vestibule of more than 80% of patients with 
disease exacerbation and in remission (Soares et al., 
2013). The number of S. aureus cells in AD patients is 
100-fold higher than in healthy individuals (Gloor et al., 
1982; Hauser et al., 1985).
S. epidermidis strains found on human skin serve 
a protective function against S. aureus strains. The basis 
for this phenomenon is the antagonistic effect of S. epi-
dermidis which produces antimicrobial peptides. Their 
task is to fight against other bacteria and to stimulate 
keratinocytes to produce antimicrobial peptides. The 
abundant number of S. aureus cells on the skin cause 
an increase in population of S. epidermidis, which is an 
additional burden for the skin (Cogen et al., 2010).
Acinetobacter spp. + +
Aerobacter sp. + –
Brevibacterium spp. + +
Candida spp. + +
Corynebacterium spp. + +
Escherichia coli + +
coagulase-negative staphylococci + ++
Klebsiella spp. +/– +
Malassezia spp. (Pityrosporum spp.) + ++
Micrococccus spp. +/– +/–
Propionibacterium spp. + +
Proteus sp. +/– +/–
Salmonella spp. +/– +
Staphylococcus aureus + ++
Streptococcus spp. +/– +
Table I
Microorganisms from the normal skin and from patients
with atopic dermatitis (AD), in alphabetical order.
Microflora of the skin normal AD
S. aureus, a pathogenic species – determinants
of pathogenicity
S. aureus is capable of synthesizing viru lence factors 
as well as of their extracellular release. These virulence 
factors demonstrate high biochemical activity. S. aureus 
exhibits a high resistance to a wide range of antibiotics 
and other antimicrobial agents.
S. aureus has the ability to adhere to components 
of the extracellular matrix. Adherence is  mediated 
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by surface adhesins that belong to the MSCRAMM 
(microbial surface components recognizing adhesive 
matrix molecules) family of proteins. Examples include 
fibronectin-binding proteins A and B, (FnBPs), colla-
gen-binding proteins, (CnBPs) and fibrinogen-binding 
proteins (Fb-BPs), (Gordon and Lowy, 2008; Schlievert 
et al., 2010). S. aureus produce numerous virulence fac-
tors that enable them to penetrate the host’s protec-
tive barriers, spread into tissue and initiate infection, 
including the following: alpha-, beta-, delta-, gamma-
hemolysins, lipase, serine proteinase (V8 protease) 
aureolysin (metalloproteinase), hyaluronidase, coagu-
lase, fibrinolysin, staphylokinase, leukocidin, especially 
the Panton-Valentine leukocidin. Other important 
virulence factors include enterotoxins (i.e. SEA, SEB, 
SEC, SED, SEE and others), the Toxic shock syndrome 
toxin-1 (TSST-1) and epidermolytic toxins (Bukowski 
et al., 2010). The pathogeni city of S. aureus also depends 
on the presence of cell wall components such as: pro-
tein A, clumping factors (ClfA and ClfB) and teichoic 
acids and the bacterial capsule polysaccharide. Other 
notable virulence factors include peptidoglycan and 
lipoteichoic acid – major constituents of the cell wall 
(Gordon and Lowy, 2008; Kobayashi and DeLeo, 2009; 
Krishna and Miller, 2012; Otto, 2014).
S. aureus as an allergen
 Colonization of the skin by S. aureus in AD causes 
the immune system to over-respond to their pres-
ence, has a toxic effect on keratinocytes and stimulates 
lymphocytes to secrete interferon (IFN) which conse-
quently leads to the development of the chronic form 
of AD. The bacteria themselves as well as their excreted 
metabolites induce the activation of T  lymphocytes, 
macrophages and antigen-presenting cells, leading, 
inter alia, to the increased production of immuno-
globulins E (IgE) and G (IgG). An elevated level of IgE 
is one of the distinctive signs of an immune response to 
an allergen. Antistaphylococcal immunoglobin E (IgE) 
has been identified and measured in patients with AD 
and its level correlates with the severity of the disease 
(Adamek-Guzik et al., 2001; Ide et al., 2004).
Furthermore a high level of IgE in patients is asso-
ciated with the coexistence of asthma, the length of the 
AD duration, as well as the severity of pruritus. Addi-
tionally, these responses trigger basophil activation 
(Reginald et al., 2011; Petry et al., 2012).
Secondary infections with S. aureus
as a consequence of AD
Secondary infections, also known as superinfec-
tions are usually bacterial, fungal or viral infections that 
occur in the presence of an existing condition. Patients 
with AD are strongly predisposed to the development 
of secondary staphylococcal infections as a  result of 
colonization of the stratum corneum by the S. aureus 
species, damage to the skin barrier or a defective 
immune response. Due to the fact that S. aureus is pre-
sent in the skin of almost all patients with AD, the mere 
presence of these bacteria is not a sufficient criterion 
for the onset of a secondary infection in skin lesions 
(Lübbe, 2003; Gong et al., 2006). 
Skin lesions in AD undergo impetiginization and 
become crusted, honey-coloured and weeping as a result 
of secondary infection. Pustules may sometimes appear 
on the skin of hands and feet (Lübbe, 2003).
The types of infections in atopic dermatitis
Patients with atopic dermatitis are exposed to infec-
tions caused by various groups of etiological factors 
as presented in Table I. The most common include: 
bacterial infections caused by various species of bac-
teria with infections predominantly caused by the 
S. aureus species; fungal infections, primarily caused 
by dermatophytes, Malassezia spp. and Candida spp., 
and viral infections, dominantly caused by the her- 
pes simplex virus (HPV) and human parvovirus (HPV). 
However, epidemiological studies clearly indicate 
that greatest significance is given to infections caused 
by S. aureus or fungi (Ring et al., 1992; Lübbe, 2003; 
Sonesson et al., 2013).
Factors favoring S. aureus infections
in patients with AD
The predisposition of patients with AD to the devel-
opment of staphylococcal infections is asso ciated with 
a defective epidermal barrier, raised adhesion activity 
of bacteria to skin cells, impaired elimination of these 
bacteria and impaired innate and acquired immunity. 
Abnormal lipid composition of the stratum corneum, 
sphingosine level reduction, altered skin pH values, 
low concentrations of IgA sweat gland secretions 
and a shortage of antimicrobial peptides, specifically 
cathelicidin LL-37, beta-defensins HBD-1, HBD-2, 
and HBD-3, as well as dermacidin, all of which have 
been reported in patients with AD, promote skin colo-
nization by S. aureus and seriously hinder the elimi-
nation of the infectious agent. Additionally, scratching 
the affected area and use of various topical treatments 
makes patients with AD particularly vulnerable and 
prone to infections (Roll et al., 2004; Boguniewicz and 
Leung, 2011).
Virulence factors produced by S. aureus in atopic 
dermatitis. Microorganisms that are present in skin 
lesions cause tissue damage by secreting enzymes and 
toxins as well as by stimulating secondary allergic 
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responses. Bacterial strains, particularly S. aureus 
strains, isolated from the skin of patients with AD are 
capable of producing many toxins and enzymes such as 
aureolysin, serine proteinase (V8 protease) or phenol-
soluble proteins known as Phenol-soluble modulins 
(PSMs), (Baran-Raunstrup et al. 1998; Międzobrodzki 
et al., 2002; Rojo et al., 2014). Staphylococcal entero-
toxins, the toxic shock syndrome toxin-1 and other tox-
ins such as alpha-toxin, play an important role in the 
development and sustenance of secondary infections 
in atopic skin lesions (Bogdali et al., 2016). Enzymes 
and other substances that are secreted by bacteria into 
the tissue of the skin lesions during secondary infec-
tions are equally important. The structural components 
of bacterial cells such as the cell wall peptidoglycan or 
the staphylococcal pigment are also present significance 
(Lomholt et al. 2005; Soares et al., 2013).
Staphylococcal superantigens – mechanism of 
action. S. aureus strains isolated from the skin of 
patients with AD release toxins, such as staphylococ-
cal enterotoxins A, B, C (staphylococcal enterotoxin A, 
B, C) and the Toxic shock syndrome toxin-1 (TSST-1) 
which penetrate the epidermis and interact with the 
various cell types involved in the immune response, 
leading to an inflammatory response orchestrated by 
T cells. These virulence factors act as superantigens and 
are produced by almost 70% of S. aureus strains (Abeck 
and Mempel, 1998; Leung et al., 2004; Soares et al., 
2013). Staphylococcal superantigens (SSAg,) trigger T 
cell activation by binding non-specifically to the T cell 
receptors (TCR) without the need for antigen presen-
tation (Otto, 2014). Superantigens penetrate the skin 
barrier and contribute to the development of a chronic 
inflammation in the atopic skin lesions. Toxins stimu-
late lymphocytes to excessively produce cytokines such 
as IL-4. Additionaly, they promote the production of 
IgE against SSAg that activate mast cells and basophils 
to release inflammatory mediators. The direct stimula-
tion of antigen presenting cells (APC) and keratino-
cytes causes the release of proinflammatory cytokines 
such as IL-1, TNF-α and IL-12 which increase the influx 
of T cells into the skin lesions. Superantigens may addi-
tionally make T cells unresponsive to topical gluco-
corticoids (GSs), making patients with AD insensitive 
to treatment with topical GSs. That is why combined 
treatment of atopic eczema with a weak glucocorticoid 
and antibiotic is more effective than treatment with 
only the potent topical corticosteroid (Schlievert et al., 
2008; Na et al., 2012; Orfali et al., 2015).
Other S. aureus virulence factors associated with 
AD. S. aureus strains are a source of proinflamma- 
tory proteins, inter alia, protein A, and have receptors 
with a high affinity to extracellular matrix proteins such 
as: collagen (collagen-binding protein, Cn-BP), fibrin-
ogen (fibrinogen-binding protein, Fb-BP), lactoferrin 
(lactoferrin-binding protein, Lf-BP), and fibronec- 
tin (fibronectin-binding protein Fn-BP) (Międzo-
brodzki et al., 1989; Naidu et al., 1991). IL-4 and IL-13 
which are present in the acute phase of eczema due 
to the increased expression of fibronectin and fibri-
nogen, enhance the adherence of staphylococci to 
inflamed skin.
The staphylococcal peptidoglycan induces the 
production of various cytokines including GM CSF 
(granulocyte macrophage colony-stimulating factor), 
a cytokine that is produced in excess in AD (Matsubara 
et al., 2004).
Other enzymes produced by S. aureus also play an 
important role in the process of infection. Published 
show that S. aureus isolated from AD patients reports 
exhibits higher proteolytic activity than those isolated 
from healthy individuals without AD (Międzobrodzki 
et al., 2002). These enzymes are known to not only 
cause damage to the skin barrier, facilitating the pen-
etration of allergens and irritants, but can also modify 
endogenous protease inhibitors, initiate and enhance 
proinflammatory and allergic responses of the human 
immunology system and trigger the secretion of IgE 
by activating Th2 cells. Among the different significant 
enzymes that are involved in the development of sec-
ondary staphylococcal infections in patients with AD, 
phenol-soluble modulins (PSMs) (Cheung et al., 2014) 
and the Panton-Valentine leukocidin (PVL) should be 
mentioned (Cavalcante et al., 2015). These enzymes 
have the capacity to lyse hosts cells enable S. aureus to 
evade immune response. Moreover, S. aureus strains 
secrete proteins that inhibit chemotaxis (chemotaxis 
inhibitory protein of staphylococci – CHIPS), impair-
ing the function of neutrophils. The onset and develop-
ment of the infection also reduces monocyte chemot-
axis (Ternowitz and Herlin, 1986; Międzobrodzki and 
Kaszycki, 2000). The golden carotenoid pigment and 
superoxide dismutase enzymes also play an important 
role in staphylococcal infections. These factors, secreted 
by S. aureus, inhibit the production of reactive oxygen 
species by the host’s neutrophils (Międzobrodzki et al., 
2008; Krishna and Miller, 2012). Another important 
virulence factor that contributes to the onset of secon-
dary staphylococcal infections in patients is aureolysin 
(metalloproteinase). This enzyme inhibits the activity 
of antimicrobial peptides such as cathelicidins. Further-
more, aureolysin is involved in the activation of other 
proteases secreted by S. aureus mainly serine proteases 
(Sabat et al., 2008; Foelster Holst et al., 2010). The alpha-
toxin has also shown to be an important virulence 
factor which can quickly induce the release of TNF-
alpha, arachidonic acid and platelet activating factor 
(PAF) from keratinocytes. The toxin forms transmem-
brane channels that act similarly to calcium channels 
(Jahreis et al., 2000). Two other staphylococcal proteins 
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also play an essential role in the pathogenesis of AD, 
namely NP-taze and p70. These proteins induce the 
secretion of IL-2 and IFN-gamma from the mononu-
clear cells isolated from the peripheral blood of patients 
with AD (Jahreis et al., 2000).
Treatment of S. aureus infections in AD
In clinical practice, it is essential to properly assess 
that the onset of the secondary bacterial infection caused 
by S. aureus and to distinguish it from the appearing 
skin lesions, that have not been affected by AD, and 
thus justifying the inclusion of antibiotic therapy. 
Leyden and colleges proposed a quantitative approach 
to this question after having observed an increased 
effectiveness of antibiotic treatment of S. aureus infec-
tions when cell concentrations on the skin were above 
106 CFU per 1 cm2 (CFU – colony forming unit). It 
turns out that quantitative bacteriology is not always 
possible in a clinical setting, that is why it is recom-
mended to firstly administer antibiotics, after having 
performed an antibiogram, for a period of 1 to 2 weeks 
after the appearance of the impetignized skin lesions, 
and then continue treatment with topical cortico-
steroids (Leyden et al., 1974).
Depending on the severity and extent of the sta-
phy lococcal infection, topical antibiotic therapy may 
be used or general antibiotic treatment is initiated. 
Affected areas of the skin may be treated by apply-
ing topical mupirocin or fusidic acid. Fusidic acid 
is available only in some European countries, North 
America and Oceania, excluding the United States. 
In recent years, more strains resistant to fusidic acid 
have appeared (fusidic acid-resistant S. aureus, FRSA), 
and so it is advisable to limit its use. Mupirocin is also 
often used to eradicate S. aureus carriage in patients 
with AD and their family members who are prone to 
frequent infections. When using this antibiotic it is 
essential to strictly follow the dosage regimen because 
there is a risk of placing selective pressure on the strain 
leading to its resistance to this antibiotic (Petry et al., 
2012; Gelmetti, 2008).
The treatment regimen recommended for patients 
with a widespread or severe secondary staphylococ-
cal infection include antibiotics such as erythromycin 
and next-generation macrolides, i.e. azithromycin or 
clarithromycin. In cases where S. aureus strains are 
resistant to macrolides, the application of penicillinase-
resistant penicillins (dicloxacillin, oxacillin, cloxacil-
lin) or next-generation cephalosporins is recommend 
(Gelmetti, 2008).
A series of studies has also been conducted that 
report the use of oral antihistamines and topical ste-
roids in the treatment of AD without the use of antibio-
tics. Results showed that S. aureus had been eradicated 
from the skin in 70% of the patients. In the group of 
patients where S. aureus was not eliminated completely 
tests revealed an elevated level of IgE and a  dimin-
ished proliferation of lymphocytes in response to SEB 
(Guzik et al., 2005).
Conclusions
Skin diseases, including atopic dermatitis, are not 
directly classified as life-threatening diseases. However, 
the symptoms and burden of the disease cause negative 
consequences in the lives of patients affected by them. 
The onset of a secondary infection caused by S. aureus 
in AD patients further increases the patient’s burden, 
complicates and hinders treatment, as well as delays 
remission. This opportunistic bacterial species has 
a wide range of virulence factors that significantly exa-
cerbate the disease. Toxins, enzymes and bacterial cell 
wall components trigger a strong immune response by 
the patient with a developing secondary infection. Data 
show that the number of patients with AD is steadily 
increasing. Finding effective medicines, as well as plan-
ning a comprehensive therapeutic strategy aimed both 
at treating disease symptoms and secondary infections 
that frequently accompany AD, is considered to be 
a big challenge both for science and practise. In order 
to obtain the desired results, it is essential to continue 
conducting research on both predisposed patients, as 
well as on the pathogenesis of infections caused by the 
opportunistic pathogen S. aureus.
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